Clinical Q, Bottom Line, Primary Outcome 1) Anemia 2) Cardiac Arrest, 3) Catherter related infections

Question 1

TRICC Clinical Q

Answer 1

Among critically ill patients, how does a restrictive transfusion strategy (hemoglobin goal of 7-9 g/dL) compare with a liberal transfusion strategy (hemoglobin goal of 10-12 g/dL) in decreasing mortality?

Question 2

TRICC Bottom line

Answer 2

In critically ill patients, restrictive transfusion (Hgb >7 g/dL) is associated with better survival compared to liberal strategy (Hgb >10).

Question 3

TRICC Primary outcome

Answer 3

30-day mortality

Question 4

TRISS Clinical Q

Answer 4

In patients with septic shock, how does a restrictive transfusion strategy (Hgb ≤ 7 g/dL) compare with a liberal transfusion strategy (Hgb ≤ 9 g/dL) in terms of 90-day mortality?

Question 5

TRISS Bottom Line

Answer 5

Patients with septic shock who underwent transfusion at a Hgb threshold of 7 g/dL had similar mortality at 90 days but used 50% fewer units of blood compared with those who underwent transfusion at a Hgb threshold of 9 g/dL.

Question 6

TRISS Primary Outcome

Answer 6

90 day mortality

Question 7

HACA Clinical Q

Answer 7

In patients with cardiac arrest due to VF or pulseless VT, does mild hypothermia improve neurologic outcomes compared with standard care normothermia?

Question 8

HACA Bottom Line

Answer 8

Among patients with return of spontaneous circulation after cardiac arrest due to VF or pulseless VT, mild therapeutic hypothermia (32-34° C) improved neurologic outcomes and reduced mortality at six months.

Question 9

HACA Primary outcome

Answer 9

favorable neurologic outcome at 6 months

Question 10

TTM Clinical Q

Answer 10

For patients with out-of-hospital cardiac arrest, does hypothermia to a goal of 33°C reduce all-cause mortality when compared to a goal of 36°C?

Question 11

TTM Bottom Line

Answer 11

In patients with out-of-hospital cardiac arrest, targeted temperature management to a goal of 33°C was not associated with reduction in all-cause mortality or improvement in neurologic outcomes when compared a goal of 36°C.

Question 12

TTM Primary Outcome

Answer 12

All-cause mortality by the end of the trial

Question 13

3 sites clinical Q

Answer 13

In critically ill patients requiring central venous access, how do complications vary by central venous catheter (CVC) access site?

Question 14

In critically ill patients requiring central venous access, how do complications vary by central venous catheter (CVC) access site?

Answer 14

In critically ill patients requiring central venous access, how do complications vary by central venous catheter (CVC) access site?

Question 15

3 sites primary outcome

Answer 15

Major catheter-related complications (bloodstream infection or symptomatic DVT)

Question 16

5

3 sites secondary outcome

Answer 16

Major mechanical complications